The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Diagnostic Nuclear Medicines Market Research Report 2025
Synopsis
Diagnostic radiopharmaceuticals. Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
The global Diagnostic Nuclear Medicines market was valued at US$ 4722 million in 2023 and is anticipated to reach US$ 7534.8 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
This report aims to provide a comprehensive presentation of the global market for Diagnostic Nuclear Medicines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diagnostic Nuclear Medicines.
Report Scope
The Diagnostic Nuclear Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diagnostic Nuclear Medicines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diagnostic Nuclear Medicines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Segment by Application
Oncology
Cardiology
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Diagnostic Nuclear Medicines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Diagnostic radiopharmaceuticals. Radiopharmaceuticals are radioisotopes bound to biological molecules able to target specific organs, tissues or cells within the human body. These radioactive drugs can be used for the diagnosis
The global Diagnostic Nuclear Medicines market was valued at US$ 4722 million in 2023 and is anticipated to reach US$ 7534.8 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
The diagnostic radioisotopes market is driven by the increasing prevalence of cancer and cardiovascular diseases, which require advanced imaging techniques for accurate diagnosis and treatment planning. Diagnostic radioisotopes are radioactive compounds used in nuclear medicine imaging to visualize and evaluate physiological processes and detect specific diseases in the body. The rise in the aging population and the need for early and precise diagnosis contribute to market growth. Moreover, advancements in radiopharmaceutical research and the development of new radioisotopes have improved the sensitivity and specificity of diagnostic imaging. However, the market also faces challenges, including the high cost of production and limited availability of some radioisotopes. Additionally, ensuring regulatory compliance and addressing concerns regarding radiation safety can pose obstacles for manufacturers and healthcare facilities. To succeed, companies must focus on research and development to offer innovative and diverse diagnostic radioisotopes, collaborate with healthcare providers to improve nuclear medicine imaging capabilities, and address the challenges to meet the increasing demand for effective and safe diagnostic imaging solutions.
This report aims to provide a comprehensive presentation of the global market for Diagnostic Nuclear Medicines, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Diagnostic Nuclear Medicines.
Report Scope
The Diagnostic Nuclear Medicines market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Diagnostic Nuclear Medicines market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Diagnostic Nuclear Medicines manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cardinal Health
GE Healthcare
Curium Pharma
Jubilant Pharma
Bracco Imaging
Novartis
SIEMENS
China Isotope & Radiation
Dongcheng
Lantheus
Eli Lilly
Segment by Type
Tc-99m
F-18
Other
Segment by Application
Oncology
Cardiology
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Diagnostic Nuclear Medicines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Diagnostic Nuclear Medicines Market Overview
1.1 Product Overview and Scope of Diagnostic Nuclear Medicines
1.2 Diagnostic Nuclear Medicines Segment by Type
1.2.1 Global Diagnostic Nuclear Medicines Market Value Comparison by Type (2024-2030)
1.2.2 Tc-99m
1.2.3 F-18
1.2.4 Other
1.3 Diagnostic Nuclear Medicines Segment by Application
1.3.1 Global Diagnostic Nuclear Medicines Market Value by Application: (2024-2030)
1.3.2 Oncology
1.3.3 Cardiology
1.3.4 Other
1.4 Global Diagnostic Nuclear Medicines Market Size Estimates and Forecasts
1.4.1 Global Diagnostic Nuclear Medicines Revenue 2019-2030
1.4.2 Global Diagnostic Nuclear Medicines Sales 2019-2030
1.4.3 Global Diagnostic Nuclear Medicines Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Diagnostic Nuclear Medicines Market Competition by Manufacturers
2.1 Global Diagnostic Nuclear Medicines Sales Market Share by Manufacturers (2019-2024)
2.2 Global Diagnostic Nuclear Medicines Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Diagnostic Nuclear Medicines Average Price by Manufacturers (2019-2024)
2.4 Global Diagnostic Nuclear Medicines Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Diagnostic Nuclear Medicines, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Diagnostic Nuclear Medicines, Product Type & Application
2.7 Diagnostic Nuclear Medicines Market Competitive Situation and Trends
2.7.1 Diagnostic Nuclear Medicines Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Diagnostic Nuclear Medicines Players Market Share by Revenue
2.7.3 Global Diagnostic Nuclear Medicines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Diagnostic Nuclear Medicines Retrospective Market Scenario by Region
3.1 Global Diagnostic Nuclear Medicines Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Diagnostic Nuclear Medicines Global Diagnostic Nuclear Medicines Sales by Region: 2019-2030
3.2.1 Global Diagnostic Nuclear Medicines Sales by Region: 2019-2024
3.2.2 Global Diagnostic Nuclear Medicines Sales by Region: 2025-2030
3.3 Global Diagnostic Nuclear Medicines Global Diagnostic Nuclear Medicines Revenue by Region: 2019-2030
3.3.1 Global Diagnostic Nuclear Medicines Revenue by Region: 2019-2024
3.3.2 Global Diagnostic Nuclear Medicines Revenue by Region: 2025-2030
3.4 North America Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.4.1 North America Diagnostic Nuclear Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Diagnostic Nuclear Medicines Sales by Country (2019-2030)
3.4.3 North America Diagnostic Nuclear Medicines Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.5.1 Europe Diagnostic Nuclear Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Diagnostic Nuclear Medicines Sales by Country (2019-2030)
3.5.3 Europe Diagnostic Nuclear Medicines Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.6.1 Asia Pacific Diagnostic Nuclear Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Diagnostic Nuclear Medicines Sales by Country (2019-2030)
3.6.3 Asia Pacific Diagnostic Nuclear Medicines Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.7.1 Latin America Diagnostic Nuclear Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Diagnostic Nuclear Medicines Sales by Country (2019-2030)
3.7.3 Latin America Diagnostic Nuclear Medicines Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Diagnostic Nuclear Medicines Market Facts & Figures by Country
3.8.1 Middle East and Africa Diagnostic Nuclear Medicines Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Diagnostic Nuclear Medicines Sales by Country (2019-2030)
3.8.3 Middle East and Africa Diagnostic Nuclear Medicines Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Diagnostic Nuclear Medicines Sales by Type (2019-2030)
4.1.1 Global Diagnostic Nuclear Medicines Sales by Type (2019-2024)
4.1.2 Global Diagnostic Nuclear Medicines Sales by Type (2025-2030)
4.1.3 Global Diagnostic Nuclear Medicines Sales Market Share by Type (2019-2030)
4.2 Global Diagnostic Nuclear Medicines Revenue by Type (2019-2030)
4.2.1 Global Diagnostic Nuclear Medicines Revenue by Type (2019-2024)
4.2.2 Global Diagnostic Nuclear Medicines Revenue by Type (2025-2030)
4.2.3 Global Diagnostic Nuclear Medicines Revenue Market Share by Type (2019-2030)
4.3 Global Diagnostic Nuclear Medicines Price by Type (2019-2030)
5 Segment by Application
5.1 Global Diagnostic Nuclear Medicines Sales by Application (2019-2030)
5.1.1 Global Diagnostic Nuclear Medicines Sales by Application (2019-2024)
5.1.2 Global Diagnostic Nuclear Medicines Sales by Application (2025-2030)
5.1.3 Global Diagnostic Nuclear Medicines Sales Market Share by Application (2019-2030)
5.2 Global Diagnostic Nuclear Medicines Revenue by Application (2019-2030)
5.2.1 Global Diagnostic Nuclear Medicines Revenue by Application (2019-2024)
5.2.2 Global Diagnostic Nuclear Medicines Revenue by Application (2025-2030)
5.2.3 Global Diagnostic Nuclear Medicines Revenue Market Share by Application (2019-2030)
5.3 Global Diagnostic Nuclear Medicines Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Cardinal Health
6.1.1 Cardinal Health Corporation Information
6.1.2 Cardinal Health Description and Business Overview
6.1.3 Cardinal Health Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Cardinal Health Diagnostic Nuclear Medicines Product Portfolio
6.1.5 Cardinal Health Recent Developments/Updates
6.2 GE Healthcare
6.2.1 GE Healthcare Corporation Information
6.2.2 GE Healthcare Description and Business Overview
6.2.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.2.4 GE Healthcare Diagnostic Nuclear Medicines Product Portfolio
6.2.5 GE Healthcare Recent Developments/Updates
6.3 Curium Pharma
6.3.1 Curium Pharma Corporation Information
6.3.2 Curium Pharma Description and Business Overview
6.3.3 Curium Pharma Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Curium Pharma Diagnostic Nuclear Medicines Product Portfolio
6.3.5 Curium Pharma Recent Developments/Updates
6.4 Jubilant Pharma
6.4.1 Jubilant Pharma Corporation Information
6.4.2 Jubilant Pharma Description and Business Overview
6.4.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio
6.4.5 Jubilant Pharma Recent Developments/Updates
6.5 Bracco Imaging
6.5.1 Bracco Imaging Corporation Information
6.5.2 Bracco Imaging Description and Business Overview
6.5.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio
6.5.5 Bracco Imaging Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Corporation Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Novartis Diagnostic Nuclear Medicines Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 SIEMENS
6.6.1 SIEMENS Corporation Information
6.6.2 SIEMENS Description and Business Overview
6.6.3 SIEMENS Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.4.4 SIEMENS Diagnostic Nuclear Medicines Product Portfolio
6.7.5 SIEMENS Recent Developments/Updates
6.8 China Isotope & Radiation
6.8.1 China Isotope & Radiation Corporation Information
6.8.2 China Isotope & Radiation Description and Business Overview
6.8.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.8.4 China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio
6.8.5 China Isotope & Radiation Recent Developments/Updates
6.9 Dongcheng
6.9.1 Dongcheng Corporation Information
6.9.2 Dongcheng Description and Business Overview
6.9.3 Dongcheng Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Dongcheng Diagnostic Nuclear Medicines Product Portfolio
6.9.5 Dongcheng Recent Developments/Updates
6.10 Lantheus
6.10.1 Lantheus Corporation Information
6.10.2 Lantheus Description and Business Overview
6.10.3 Lantheus Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Lantheus Diagnostic Nuclear Medicines Product Portfolio
6.10.5 Lantheus Recent Developments/Updates
6.11 Eli Lilly
6.11.1 Eli Lilly Corporation Information
6.11.2 Eli Lilly Diagnostic Nuclear Medicines Description and Business Overview
6.11.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Eli Lilly Diagnostic Nuclear Medicines Product Portfolio
6.11.5 Eli Lilly Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Diagnostic Nuclear Medicines Industry Chain Analysis
7.2 Diagnostic Nuclear Medicines Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Diagnostic Nuclear Medicines Production Mode & Process
7.4 Diagnostic Nuclear Medicines Sales and Marketing
7.4.1 Diagnostic Nuclear Medicines Sales Channels
7.4.2 Diagnostic Nuclear Medicines Distributors
7.5 Diagnostic Nuclear Medicines Customers
8 Diagnostic Nuclear Medicines Market Dynamics
8.1 Diagnostic Nuclear Medicines Industry Trends
8.2 Diagnostic Nuclear Medicines Market Drivers
8.3 Diagnostic Nuclear Medicines Market Challenges
8.4 Diagnostic Nuclear Medicines Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
